DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-31 15:51 |
DBV Technologies Announces Plan to Implement ADS Ratio Change
|
English | 178.8 KB | ||
| 2024-05-31 15:51 |
DBV Technologies annonce son intention de modifier le ratio d'ADS
|
French | 179.0 KB | ||
| 2024-05-30 22:30 |
DBV Technologies to Participate in Upcoming EAACI 2024 Congress
|
English | 165.0 KB | ||
| 2024-05-30 22:30 |
DBV Technologies participera au prochain congrès EAACI 2024
|
French | 223.9 KB | ||
| 2024-05-17 22:30 |
DBV Technologies annonce son intention de modifier le ratio d'ADS
|
French | 190.4 KB | ||
| 2024-05-17 22:30 |
DBV Technologies Announces Plan to Implement ADS Ratio Change
|
English | 179.2 KB | ||
| 2024-05-16 22:30 |
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024
|
French | 179.9 KB | ||
| 2024-05-16 22:30 |
DBV Technologies Announces Results of its 2024 Combined General Meeting
|
English | 180.0 KB | ||
| 2024-05-09 22:30 |
Participation de DBV Technologies aux conférences investisseurs en mai
|
French | 145.5 KB | ||
| 2024-05-09 22:30 |
DBV Technologies to Participate in Upcoming Investor Conferences
|
English | 125.3 KB | ||
| 2024-05-07 22:30 |
DBV Technologies publie ses résultats financiers du premier trimestre 2024 et f…
|
French | 301.4 KB | ||
| 2024-05-07 22:30 |
DBV Technologies Reports First Quarter 2024 Financial Results and Business Upda…
|
English | 192.7 KB | ||
| 2024-04-25 22:30 |
Assemblée Générale Mixte du 16 mai 2024
|
French | 144.2 KB | ||
| 2024-04-25 22:30 |
Combined General Meeting of May 16, 2024
|
English | 143.5 KB | ||
| 2024-04-04 22:43 |
Information regarding the total number of voting rights and total number of sh…
|
English | 499.7 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
